Key Highlights
- QuidelOrtho (NASDAQ:QDEL) reported third-quarter 2026 Revenue of USD 618.9 million on November 3, 2026, down 11.6% from USD 699.9 million, with Point of Care sales down 27.3% to USD 119.6 million.
- The GAAP net loss was USD 53.8 million, or USD 0.78 per share, against a USD 733.0 million loss, or USD 10.78, a year earlier; adjusted diluted EPS fell to USD 0.31 from USD 0.80.
- Full-year adjusted EPS guidance was narrowed to USD 0.65 to USD 0.70 from USD 0.65 to USD 0.90, and the revenue range was trimmed to USD 2.52 billion to USD 2.54 billion.
- Borrowings totaled about USD 2.94 billion against cash of USD 166.4 million at September 27, 2026, while free Cash Flow in the quarter was just USD 0.3 million.
Point of Care Slump Drives Revenue Down 11.6%
QuidelOrtho (NASDAQ:QDEL) released results for the quarter ended September 27, 2026 on November 3, 2026. Labs revenue fell 5.5% to USD 353.2 million and immunohematology was flat at USD 142.0 million, while Point of Care dropped 27.3% on a softer respiratory season. The diagnostics maker's adjusted EBITDA was USD 148.0 million, a 23.9% Margin against 25.3%, and the GAAP operating loss was USD 7.5 million. Management said Labs and Immunohematology remained solid, so the weakness was concentrated in respiratory testing, which can swing with the severity of flu and COVID seasons. Nine-month revenue was USD 1,869.6 million against USD 2,006.6 million a year earlier.
A Huge Prior-Year Loss Skews the EPS Comparison
Published market data lists a 1 year EPS change of 122.63% and a price of about USD 14.14, up 0.36%, from an undated screen that could not be matched to the filing. The GAAP loss per share narrowed from USD 10.78 to USD 0.78 only because the year-earlier loss of USD 733.0 million was far larger; the release extract did not state its cause, so none is assumed. On the adjusted basis, EPS fell about 61%, from USD 0.80 to USD 0.31, simple arithmetic. Dividing the prior-year loss by its per-share figure implies about 68 million shares, so Market Value is near USD 1 billion, a rough estimate and not a verified market cap. Share count and price were not matched to a filing.
Guidance Cut, Restructuring and the Debt Load
The company trimmed the top of its 2026 ranges: adjusted EBITDA of USD 540 million to USD 545 million from USD 540 million to USD 560 million, and adjusted EPS of USD 0.65 to USD 0.70. It expects annual savings of more than USD 80 million in 2027 and one-time restructuring charges of about USD 30 million to USD 35 million in the fourth quarter, as it reorganizes around Core Diagnostics and Point of Care Diagnostics. Borrowings of about USD 2.94 billion are large relative to USD 166.4 million of cash, and nine-month free cash flow was negative USD 202.8 million, a key risk for QuidelOrtho (NASDAQ:QDEL).
Where Things Stand
Because respiratory Demand fell short and the company removed the top of its earlier range. QuidelOrtho (NASDAQ:QDEL) still reports solid Labs and Immunohematology results, but a 27.3% drop in Point of Care, adjusted EPS of USD 0.31 and a leveraged Balance Sheet explain the trim. The USD 80 million 2027 savings target and the fourth-quarter restructuring charges are next to watch, with the coming respiratory season the swing factor. The material reviewed gave no verified date for the next report, and guidance remains an estimate.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...